UMB Non-Human Primate Core

$56,656U54FY2013AINIH

University Of Maryland Baltimore, Baltimore MD

Investigators

Linked publications & trials

Paper 38770087 Paper 37766204 Paper 37381064 Paper 35881640 Paper 32741672 Paper 32719120 Paper 32241221 Paper 32205255 Paper 31629569 Paper 31412039 Paper 31194282 Paper 30951606 Paper 30923521 Paper 30849494 Paper 30836838 Paper 30726215 Paper 30404186 Paper 30346608 Paper 29963499 Paper 29735417 Paper 29254983 Paper 28887533 Paper 28645238 Paper 28468881 Paper 28286804 Paper 28054965 Paper 27708164 Paper 27634430 Paper 27474443 Paper 27453902 Paper 27222487 Paper 27030587 Paper 27013661 Paper 26998925 Paper 26958926 Paper 26912630 Paper 26904753 Paper 26792745 Paper 26778280 Paper 26624016 Paper 26581979 Paper 26567510 Paper 26513362 Paper 26351285 Paper 26196739 Paper 26164699 Paper 26056282 Paper 26041706 Paper 26038567 Paper 25986219 Paper 25902362 Paper 25872480 Paper 25852164 Paper 25844088 Paper 25648517 Paper 25530917 Paper 25336460 Paper 25305323 Paper 25283728 Paper 25210190 Paper 25197089 Paper 25184386 Paper 25135687 Paper 25126784 Paper 25033732 Paper 24983203 Paper 24951806 Paper 24837414 Paper 24762309 Paper 24760892 Paper 24741084 Paper 24671194 Paper 24643777 Paper 24623629 Paper 24586873 Paper 24576301 Paper 24556791 Paper 24550726 Paper 24522922 Paper 24516383 Paper 24429069 Paper 24379294 Paper 24375134 Paper 24374193 Paper 24365382 Paper 24335292 Paper 24332855 Paper 24319627 Paper 24273182 Paper 24225592 Paper 24105766 Paper 24099872 Paper 24069471 Paper 24068738 Paper 24061146 Paper 23989728 Paper 23980175 Paper 23958904 Paper 23935121 Paper 23903543

Abstract

Optimal utilization of nonhuman primates for biodefense and emerging pathogens research requires a facility where animals are housed in appropriate biocontainment and research personnel experienced in the methodologies required for infectious disease research and vaccine development. The non-human primate (NHP) Core at the University of Maryland, Baltimore will provide state-of-the-art animal biosafety levels (ABSL) 2 and 3 facilities for biodefense research using nonhuman primates. Currently, our facilities support projects aimed at developing vaccines against anthrax, smallpox and S. dysenteriae 1 vaccines. These projects use NHPs as animal models for studying disease pathogenesis and testing vaccine efficacy and safety. Our facilities fully support biohazard research at ABSL-2 and 3 levels and meet all NIH/CDC guidelines. Our expert personnel will provide consultation services to investigators planning to use the NHP core for biohazard studies. We will make available our extensive experience in the utilization of NHPs for pathogenesis research and vaccine development for various CDC category A, B and C agents. Hence, the NHP core will be a very important component to support proposals aimed at developing innovative therapeutics against bioterrorism agents.

View original record on NIH RePORTER →